| Literature DB >> 32181284 |
Lu Yang1,2,3,4,5, Xiuhong Xue1,2,3,4,5,6, Ting Zeng1,2,3,4,5, Xuemei Chen1,2,3,4,5, Qin Zhao1,2,3,4,5, Xuemei Tang2,3,4,5,7, Jun Yang8, Yunfei An1,2,3,4,5,7, Xiaodong Zhao1,2,3,4,5,7.
Abstract
Mutations in the gene encoding transfer RNA (tRNA) nucleotidyltransferase, CCA-adding 1 (TRNT1), an enzyme essential for the synthesis of the 3'-terminal CCA sequence in tRNA molecules, are associated with a rare syndrome of congenital sideroblastic anemia, B cell immunodeficiency, periodic fevers, and developmental delay (SIFD). Clinical manifestations and immunological phenotypes were assessed in a Chinese patient with novel compound heterozygous mutations in TRNT1. The patient required multiple hospitalizations starting at the age of 2 years for recurrent fevers without an infective cause. During the febrile episode, the patient was found to have microcytic hypochromic anemia, B cell lymphopenia, and hypogammaglobulinemia. Targeted gene sequencing identified novel compound heterozygous mutations in the TRNT1 gene (c.525delT, p.Leu176X; c.938T>C, p.Leu313Ser). Immunophenotyping revealed increased CD8+ T cells, CD4+ terminally differentiated effector memory helper T lymphocytes (CD4 TEMRA), and CD4+ effector memory lymphocytes (CD4 EM). Analysis of CD4+ T subsets identified decreased T follicular helper cells (Tfh) with a biased phenotype to Th2-like cells. The patient also showed a lower percentage of switched memory B (smB) cells. Additionally, defects in the cytotoxicity of the patient's NK and γδT cells were shown by CD107alpha expression. In conclusion, T RNT1 mutations may lead to multiple immune abnormality especially humoral and cytotoxicity defects, which indicate that SIFD is not only suffered 'Predominantly antibody deficiencies' in IUIS classification system, and further studies are needed to understand the pathogenesis of immunodeficiency in these patients.Entities:
Keywords: Mild phenotype; Multiple immune defects; Novel mutations; SIFD; TRNT1
Year: 2020 PMID: 32181284 PMCID: PMC7063413 DOI: 10.1016/j.gendis.2020.01.005
Source DB: PubMed Journal: Genes Dis ISSN: 2352-3042
Figure 1Clinical and genetic characterization of the patient. (A) The complete blood counts showed increased platelets (blue), fluctuations in white blood cell numbers (gray) and hemoglobin levels (red), and low mean corpuscular volume (MCV; purple) and mean corpuscular hemoglobin (MCH; green). The normal reference ranges are indicated as following: WBC 4-12*10ˆ9/L; PLT 100–380*10ˆ9/L; Hb 110–150 g/L; MCV 80-100 fL; MCH 26–32 pg. (B) B cell numbers were initially low, but gradually normalized (red). The normal reference ranges are indicated as following: CD3+ T 55–78%; CD4+ T 27–53%; CD8+ T 19–34%; CD19+ B 10–31%; NK 4–26%. (C) Low levels of IgG (red) were observed. * indicates a measurement taken after immunoglobulin supplementation therapy. The normal reference ranges are indicated as following: IgG 5.3–21.9 g/L; IgM 0.5–2.3 g/L; IgA 0.6–3.5 g/L. (D) Sanger sequencing confirmed compound heterozygous mutations in TRNT1 in the patient. The black arrows indicate the locations of mutations. The reference transcript sequence of TRNT1 is NM_182916. (E) The structural impact of mutant Leu313Ser was analyzed on the basis of template of 1OU5 from PDB by Swiss-PdbViewer. Carbon atoms in white, oxygen in red and nitrogen in blue. Hydrogen bonds are shown as dotted lines. Residues Leu313/Ser313 are highlighted in purple.
Immunophenotyping of peripheral blood lymphocyte subsets.
| 2017.07(2 y 10 m) | 2019.07(4 y 10 m) | |||||||
|---|---|---|---|---|---|---|---|---|
| Percentage | Reference | numbers/μl | Reference | Percentage | Reference | numbers/μl | Reference | |
| T cells | 83.7↑ | 53.4–72.0 | 4124.4↑ | 1775.5–3953.0 | 74.7 | 59.5–75.6 | 2548.0 | 1480.3–2847.3 |
| CD8+ T cells | 30.3 | 16.3–30.0 | 1843.8↑ | 531.2–1520.7 | 33.5↑ | 19.7–32.0 | 1142.7↑ | 552.6–1127.3 |
| CD8 naïve | 45.1 | 38.2–86.2 | 831.6 | 294.6–971.3 | 40.9 | 38.0–79.1 | 467.4 | 293.4–768.4 |
| CD8 TEMRA | 24.5 | 0.5–24.5 | 451.7↑ | 3.1–294.0 | 28.6↑ | 1.3–22.9 | 326.8↑ | 9.1–209.8 |
| CD8 CM | 26.4 | 6.7–34.1 | 486.8↑ | 54.2–379.4 | 25.4 | 11.9–36.9 | 290.2 | 79.6–350.4 |
| CD8 EM | 4.05 | 0.6–12.0 | 74.7 | 4.0–163.0 | 5.0 | 1.1–14.5 | 57.1 | 7.9–104.2 |
| CD4+ T cells | 58.1↑ | 26.2–45.5 | 2074.5 | 948.2–2476.5 | 36.2 | 28.5–41.1 | 1233.7 | 767.3–1592.5 |
| CD4 naïve | 49.0 | 46.4–81.2 | 1016.5 | 529.7–1836.6 | 44.7 | 40.8–72.7 | 551.5 | 338.7–1037.0 |
| CD4 TEMRA | 1.5↑ | 0.0–0.5 | 30.7↑ | 0.0–12.3 | 2.4↑ | 0.0–1.5 | 29.9↑ | 0.0–16.7 |
| CD4 CM | 39.1 | 17.1–47.6 | 811.1↑ | 220.4–799.7 | 41.8 | 21.7–52.7 | 515.7 | 232.1–600.9 |
| CD4 EM | 10.4↑ | 0.9–5.2 | 215.8↑ | 14.2–93.5 | 11.1↑ | 1.9–9.2 | 136.9↑ | 20.5–96.8 |
| TCRαβ+DNT | 1.3 | 0.57–2.4 | 54.3 | 16.1–57.6 | 1.3 | 0.2–2.4 | 33.4 | 3.8–49.5 |
| γδ T cells | 18.5↑ | 5.1–17.6 | 763.0↑ | 127.7–520.1 | 19.4 | 7.0–19.6 | 494.3↑ | 133.7–427.8 |
| B cells | 5.2↓ | 13.9–30.5 | 253.9↓ | 537.1–1464.4 | 21.0 | 10.5–21.8 | 714.7 | 303.5–777.3 |
| Memory B | 12.3 | 3.6–18.6 | 31.2↓ | 33.1–145.9 | 6.0↓ | 8.6–20.2 | 43.0 | 37.7–114.8 |
| Naïve B | 70.6 | 59.6–85.3 | 179.3↓ | 371.5–1196.7 | 85.9↑ | 52.0–75.8 | 614.0↑ | 171.5–469.3 |
| Transitional B | 28.9↑ | 4.7–15.7 | 73.4 | 33.5–180.8 | 9.4 | 3.4–11.2 | 67.1↑ | 14.4–59.6 |
| Plasmablasts B | 8.2 | 0.6–10.3 | 20.7 | 4.0–87.6 | 2.5 | 0.8–9.8 | 17.9 | 3.9–39.8 |
| NK cells | 9.7 | 6.5–22.2 | 477.2 | 241.1–977.9 | 4.1↓ | 7.8–21.- | 138.8↓ | 227.5–667.8 |
| CD4/CD8 | 1.1 | 1.1–2.5 | – | – | 1.1 | 1.0–2.1 | – | – |
TEMRA: terminally differentiated effector memory helper T lymphocytes; CM: central memory; EM: effector memory.
Naïve, CD45RA+CD27+; TEMRA, CD45RA+CD27−; CM, CD45RA−CD27+; EM, CD45RA−CD27−; TCRαβ+DNT, CD3+TCRαβ+CD4−CD8−; Memory B cells, CD19+CD27+IgD−; naïve B cells, CD19+CD27−IgD+; transitional B cells, CD19+CD24++CD38++; plasmablasts, CD19+CD24−CD38++.
The age-matched reference values were obtained from one previous study (Ding et al,2018) focusing on peripheral lymphocyte phenotyping in healthy Chinese children.
Figure 2Skewed peripheral T cell subsets in a patient with TRNT1 deficiency. (A) and (B) Compared with healthy controls, the patients showed normal percentages of Treg and expression of CTLA4 and Helios. (C) and (D) The percentage of cTfh cells decreased while the Tfr cell frequency remained normal. (E) The non-cTfh memory cells (CD3+CD4+CXCR5−CD45RA−) were skewed to a Th2 phenotype. (F) The cTfh cells (CD3+CD4+CXCR5+CD45RA−) were skewed to a Th2-like phenotype, and Th1/17-like cells were reduced. (G)–(I) Percentages of Treg, cTfh, Tfr, non-cTfh memory subsets, and cTfh subsets in the patient and in healthy controls (n = 12).
Figure 3CDR3 spectratyping revealed a normal polyclonal TCR repertoire. The numbers of Vβ-specific primers were indicated on the right upper corner and a Gaussian distribution of blue peaks indicated polyclone of TCRVβ subfamilies.
Figure 4The proliferation of CD4+T cells (left panel), CD8+ T cells (middle panel) and CD19+ B cells (right panel) was normal in patient, compared with age-matched healthy control. Red peak: unstimulated; blue peak: after stimulated.
Figure 5Abnormal B cell phenotype of a patient with TRNT1 deficiency. (A) and (B) B cell subsets were analyzed when the patient was 2 years, 10 months of age, and 2 years later. The patient consistently showed reduced smB and increased IgMhi B cells. (C) Percentages of smB and MZ-like B cells in the patient and healthy controls (n = 12).
Figure 6When stimulated with K562 cells, the patient's NK and γδT cells showed less CD107a expression than healthy controls. (A) The patient showed decreased percentage of CD107a+ cells in NK and γδT cells. (B) Percentage of CD107a+ cells in the patient and healthy controls (n = 5).